Key facts
- Diabeloop’s last known valuation is $57.1M (Sep 2019).
- It has raised $141.3M; the latest was Later Stage VC ($630K) in Mar 2025.
- Notable investors include UI Investissement, Supernova Invest, Turenne Groupe, Crédit Agricole Alpes Développement, Odyssee Venture — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Diabeloop
- ·The full record, as it builds
Funding rounds
No funding rounds for Diabeloop are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diabeloop
Developer of an AI-based blood sugar monitoring device designed to improve diabetes treatment. The company's device automatically delivers the appropriate dose of insulin to patients and has a sensor that measures patients' glucose levels, a pump that delivers insulin, and a smartphone application with an embedded algorithm and patient interface that links the sensor and the pump, enabling patients to have a lighter mental load and live their lives without interruptions.
- Sector
- Healthcare
- HQ
- Grenoble, France
- Founded
- 2015
- Employees
- 87
- Website
- diabeloop.fr/
- Ownership
- Privately Held (backing)
Diabeloop doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diabeloop shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diabeloop in its N-PORT filings yet. We sweep new filings monthly.